PharmaTher targets personalized peptide, psychedelic medicines using MEDBOTX 3D printing and AI tools

• PharmaTher set a new strategy to build a personalized-medicine business focused on peptides and psychedelics using its MEDBOTX 3D-printing platform.
• Plans call for AI-driven formulation tools to enable patient-specific dosing, controlled-release profiles, multi-phase products, and alternative delivery formats.
• Commercialization planning centers on a capital-efficient model spanning proprietary formulations, partnerships with 503A compounding pharmacies and hospitals, and supplying MEDBOTX systems.
• Strategy targets potential demand from rising regulatory attention to peptides ahead of the FDA advisory committee meeting on July 23-24, 2026.
• Pipeline planning also leans on a more defined U.S. path for psychedelic trials following the FDA’s first clinical guidance issued in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmather Holdings Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607150800NEWSFILECNPR____20260715_305165_1) on July 15, 2026, and is solely responsible for the information contained therein.